| Market Capitalization (Millions $) |
1,114 |
| Shares
Outstanding (Millions) |
144 |
| Employees |
48 |
| Revenues (TTM) (Millions $) |
235 |
| Net Income (TTM) (Millions $) |
6 |
| Cash Flow (TTM) (Millions $) |
35 |
| Capital Exp. (TTM) (Millions $) |
0 |
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on the development of novel therapies for the treatment of lupus nephritis and other autoimmune diseases. The company is headquartered in Victoria, British Columbia, Canada, and was founded in 199
The companyes flagship drug candidate is voclosporin, which is a calcineurin inhibitor under development for the treatment of lupus nephritis. Lupus nephritis is a serious autoimmune disease that affects the kidneys and can lead to kidney failure. Currently, there are no FDA-approved treatments for lupus nephritis.
Aurinia is conducting a Phase 3 clinical trial of voclosporin in lupus nephritis, which is expected to be completed in 202 The company has also conducted Phase 2 trials of voclosporin in other autoimmune diseases, including dry eye syndrome and non-infectious uveitis.
In addition to voclosporin, Aurinia is developing a pipeline of other novel therapies for autoimmune diseases. The companyes pipeline includes drugs that target the complement system, a complex system of proteins that play a role in immune response and inflammation.
Aurinia has a strong intellectual property (IP) portfolio, including patents related to the composition of matter and the use of voclosporin and other compounds for the treatment of autoimmune diseases. The company has also formed strategic partnerships with other biopharmaceutical companies to develop and commercialize its drug candidates.
Aurinia has a talented and experienced management team, including CEO Peter Greenleaf, who has over 20 years of experience in the pharmaceutical industry. The company also has a strong financial position, with over $400 million in cash and investment securities as of December 31, 2020.
Overall, Aurinia Pharmaceuticals Inc. is a leading biopharmaceutical company focused on the development of novel therapies for the treatment of lupus nephritis and other autoimmune diseases. With a strong pipeline of drug candidates, a robust IP portfolio, and a talented management team, Aurinia is well-positioned to make a meaningful impact in the field of autoimmune diseases.
Company Address: #140, 14315 - 118 Avenue Edmonton 0 AB
Company Phone Number: 744-2487 Stock Exchange / Ticker: NASDAQ AUPH
|
3.78% 